INOVIO Gets $71 Million Contract from U.S. Department of Defense

On June 23, INOVIO (INO) announced that it received a $71 million contract from the U.S. Department of Defense in order to support large-scale manufacturing of the company’s CELLECTRA® 3PSP device. Both the company’s proprietary CELLECTRA® 3PSP smart device and the CELLECTRA® 2000 deliver INO-4800 directly into the skin. INO-4800 is the company’s COVID-19 vaccine that is currently in Phase 1 clinical trials with Phase 2/3 set to start later this summer. The CELLECTRA® 3PSP is a small, portable device that runs on “AA batteries” and can be easily stockpiled in preparation for a global pandemic.


Sonal issued a news alert at 7:30 am. The next trade took place at 7:31 am for $16.35. INOVIO closed above $20 on the event day, and the stock price continued to rise over the next four trading sessions. INOVIO closed at $31.69 on June 29 for a five-day gain of 94%.29


Visit the Knowledge Center for more information about trading contract awards.

To see the latest weekly webinar, you can visit our Live Webinar page.

Subscribe here if you would like to start receiving these signals in real-time and start trading!